health news today obesity drugs glp-1 World Organization recommends for Alarming rise in weight loss

Monitoring and follow-up: Regular follow-up during the first 3-6 months of therapy allows for symptom assessment, dose optimization, and early identification of complications

Weight loss goals should be personalized to each patient and weighed against risks of contributing to sarcopenia

We'll, we'll see how it goes

No statistical methods were applied to predetermine the sample size for in vivo pharmacology experiments

View at Publisher | View at Google Scholar Zhang L et al

A systematic review executed on animal and human studies alongside case studies (93) demonstrated a dearth of human evidence on the excretion of GLP-1 agonists in breast milk, even though GLP-1 agonists, being large peptides, could be precisely present in human milk, although the exact amount is unclear (89)